Insider Selling: Simulations Plus (NASDAQ:SLP) Director Sells $77,023.88 in Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter Woltosz sold 4,177 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $18.44, for a total transaction of $77,023.88. Following the completion of the sale, the director directly owned 3,202,131 shares in the company, valued at $59,047,295.64. This trade represents a 0.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Simulations Plus Price Performance

Shares of SLP opened at $18.27 on Thursday. The firm has a 50 day simple moving average of $16.40 and a 200-day simple moving average of $15.48. The stock has a market cap of $369.05 million, a price-to-earnings ratio of -5.84 and a beta of 1.30. Simulations Plus, Inc. has a 1-year low of $11.09 and a 1-year high of $21.01.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Thursday, April 9th. The technology company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.08. The company had revenue of $24.29 million during the quarter, compared to the consensus estimate of $21.66 million. Simulations Plus had a positive return on equity of 16.21% and a negative net margin of 77.96%. On average, equities analysts expect that Simulations Plus, Inc. will post 0.8 earnings per share for the current fiscal year.

Institutional Trading of Simulations Plus

Large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. acquired a new position in shares of Simulations Plus during the second quarter worth about $25,000. Quarry LP purchased a new position in Simulations Plus in the 3rd quarter valued at about $28,000. GAMMA Investing LLC grew its stake in shares of Simulations Plus by 26.0% during the second quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock valued at $52,000 after acquiring an additional 585 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Simulations Plus by 59.3% during the first quarter. PNC Financial Services Group Inc. now owns 4,485 shares of the technology company’s stock worth $53,000 after acquiring an additional 1,669 shares during the last quarter. Finally, Fifth Third Bancorp purchased a new stake in shares of Simulations Plus during the first quarter worth about $54,000. 78.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. William Blair lowered shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a research report on Wednesday, June 17th. Wall Street Zen lowered Simulations Plus from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings upgraded Simulations Plus from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, June 5th. Craig Hallum lowered shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price objective on the stock. in a report on Thursday, June 18th. Finally, TD Cowen lowered their target price on shares of Simulations Plus from $19.00 to $16.00 and set a “hold” rating for the company in a report on Friday, April 10th. One equities research analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $19.88.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.